

**Journalbeiträge**

1. Amaral JD, Herrera F, Rodrigues PM, Dionísio PA, Outeiro TF, Rodrigues CMP (2013) Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system. *BIOCHEM PHARMACOL*, 85(6): 745-52.
2. Amaral M, Levy C, Heyes DJ, Lafite P, Outeiro TF, Giorgini F, Leys D, Scrutton NS (2013) Structural basis of kynurenine 3-monooxygenase inhibition. *NATURE*, 496(7445): 382-5.
3. Amaral M, Outeiro TF, Scrutton NS, Giorgini F (2013) The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease. *J MOL MED*, 91(6): 705-13.
4. Basso E, Antas P, Marijanovic Z, Gonçalves S, Tenreiro S, Outeiro TF (2013) PLK2 modulates  $\alpha$ -synuclein aggregation in yeast and mammalian cells. *MOL NEUROBIOL*, 48(3): 854-62.
5. Donmez G, Outeiro TF (2013) SIRT1 and SIRT2: emerging targets in neurodegeneration. *EMBO MOL MED*, 5(3): 344-52.
6. Eisbach SE, Outeiro TF (2013) Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. *J MOL MED*, 91(6): 693-703.
7. Fagerqvist T, Näsström T, Ihse E, Lindström V, Sahlin C, Tucker SMF, Kasaryan A, Karlsson M, Nikolajeff F, Schell H, Outeiro TF, Kahle PJ, Lannfelt L, Ingelsson M, Bergström J (2013) Off-pathway  $\alpha$ -synuclein oligomers seem to alter  $\alpha$ -synuclein turnover in a cell model but lack seeding capability in vivo. *AMYLOID*, 20(4): 233-44.
8. Faria C, Jorge CD, Borges N, Tenreiro S, Outeiro TF, Santos H (2013) Inhibition of formation of  $\alpha$ -synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease. *BICHIM BIOPHYS ACTA*, 1830(8): 4065-72.
9. Gonçalves S, Outeiro TF (2013) Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. *MOL NEUROBIOL*, 47(3): 1081-92.
10. Guerreiro PS, Huang Y, Gysbers A, Cheng D, Gai WP, Outeiro TF, Halliday GM (2013) LRRK2 interactions with  $\alpha$ -synuclein in Parkinson's disease brains and in cell models. *J MOL MED*, 91(4): 513-22.
11. Lopes da Fonseca T, Correia A, Hasselaar W, van der Linde HC, Willemsen R, Outeiro TF (2013) The zebrafish homologue of Parkinson's disease ATP13A2 is essential for embryonic survival. *BRAIN RES BULL*, 90: 118-26.
12. Marques S, Outeiro TF (2013) Epigenetics in Parkinson's and Alzheimer's diseases. *Subcell Biochem*, 61: 507-25.
13. Pais TF, Szegő ÉM, Marques O, Miller-Fleming L, Antas P, Guerreiro P, de Oliveira RM, Kasapoglu B, Outeiro TF (2013) The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. *EMBO J*, 32(19): 2603-16.
14. Repici M, Straatman KR, Balduccio N, Enguita FJ, Outeiro TF, Giorgini F (2013) Parkinson's disease-associated mutations in DJ-1 modulate its dimerization in living cells. *J MOL MED*, 91(5): 599-611.
15. Schildknecht S, Gerding HR, Karreman C, Drescher M, Lashuel HA, Outeiro TF, Di Monte DA, Leist M (2013) Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. *J NEUROCHEM*, 125(4): 491-511.
16. Szegő ÉM, Outeiro TF, Kermer P, Schulz JB (2013) Impairment of the septal cholinergic neurons in MPTP-treated A30P  $\alpha$ -synuclein mice. *NEUROBIOL AGING*, 34(2): 589-601.
17. Taschenberger G, Toloe J, Tereshchenko J, Akerboom J, Wales P, Benz R, Becker S, Outeiro TF, Looger LL, Bähr M, Zweckstetter M, Kügler S (2013)  $\beta$ -synuclein aggregates and induces neurodegeneration in dopaminergic neurons. *ANN NEUROL*, 74(1): 109-18.
18. Tenreiro S, Munder MC, Alberti S, Outeiro TF (2013) Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. *J NEUROCHEM*, 127(4): 438-52.
19. Vicente Miranda H, Xiang W, de Oliveira RM, Simões T, Pimentel J, Klucken J, Penque D, Outeiro TF (2013) Heat-mediated enrichment of  $\alpha$ -synuclein from cells and tissue for assessing post-translational modifications. *J NEUROCHEM*, 126(5): 673-84.
20. Vittori A, Orth M, Roos RAC, Outeiro TF, Giorgini F, Hollox EJ, REGISTRY investigators of the European Huntington's Disease Network (2013)  $\beta$ -Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease. *J Huntingtons Dis*, 2(1): 107-124.
21. Wales P, Pinho R, Lázaro DF, Outeiro TF (2013) Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. *J PARKINSON DIS*, 3(4): 415-59.